{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:03:33Z","timestamp":1772255013187,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RC 56\/22"],"award-info":[{"award-number":["RC 56\/22"]}]},{"name":"Institute for Maternal and Child Health IRCCS","award":["RC 56\/22"],"award-info":[{"award-number":["RC 56\/22"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acyclovir and ganciclovir comprise the prophylaxis and treatment of herpesvirus and cytomegalovirus infections occurring in immunocompromised patients. Their therapeutic drug monitoring is fundamental because of interindividual variability leading to side effects and drug resistance and is performed through several techniques, such as liquid chromatography coupled with UV spectrophotometry (HPLC-UV) or mass spectrometry (LC-MS\/MS). Therefore, we developed and validated a low-cost, non-time-consuming, and low-sample-consuming HPLC-UV method. Briefly, 100 \u00b5L of sample was used for sample preparation, mainly consisting of precipitation through organic solvent. In total, 20 \u00b5L was injected into the instrument. Chromatographic separation was obtained eluting mobile phases A (10 mM ammonium formiate 0.01% formic acid) and B (acetonitrile) on a Poroshell 120 SB-C8 2.1 \u00d7 150 mm, 2.7 \u00b5m for 12 min isocratically (97:3; A:B) at a flow rate of 0.2 mL\/min. The linearity range (0.5\u201340 mg\/L) of the method allowed us to quantify both the Cmin and Cmax of acyclovir and ganciclovir. Plasma concentrations measured on a small cohort of patients undergoing acyclovir (31) and ganciclovir (9) treatment by the proposed method and the LC-MS\/MS methods, already in use, were significantly correlated. The proposed HPLC-UV method may be implemented in diagnostics as an alternative method in case of the unavailability of the LC-MS\/MS system.<\/jats:p>","DOI":"10.3390\/ijms25052685","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T07:51:39Z","timestamp":1708933899000},"page":"2685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development and Validation of an HPLC-UV Method for the Quantification of Acyclovir and Ganciclovir in the Plasma of Pediatric Immunocompromised Patients"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-6190","authenticated-orcid":false,"given":"Martina","family":"Franzin","sequence":"first","affiliation":[{"name":"Institute for Maternal and Child Health, IRCCS \u201cBurlo Garofolo\u201d, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Ruoso","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health, IRCCS \u201cBurlo Garofolo\u201d, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Del Savio","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health, IRCCS \u201cBurlo Garofolo\u201d, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Addobbati","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health, IRCCS \u201cBurlo Garofolo\u201d, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2019.09.003","article-title":"Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: Systematic review and meta-analysis","volume":"26","author":"Bitterman","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: Prevention, Diagnosis and Therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Huntjens, D.W., Dijkstra, J.A., Verwiel, L.N., Slijkhuis, M., Elbers, P., Welkers, M.R.A., Veldkamp, A.I., Kuijvenhoven, M.A., de Leeuw, D.C., and Abdullah-Koolmees, H. (2023). Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010163"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"865871","DOI":"10.3389\/fphar.2022.865871","article-title":"Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients","volume":"13","author":"Maximova","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_7","first-page":"457","article-title":"Drug-induced impairment of renal function","volume":"7","author":"Pazhayattil","year":"2014","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1038\/s41467-021-24509-7","article-title":"NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir","volume":"12","author":"Nishii","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kacirova, I., Urinovska, R., and Sagan, J. (2022). Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113852"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic Drug Monitoring of Ganciclovir: Where Are We?","volume":"44","author":"Edwina","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3889\/oamjms.2015.011","article-title":"Determination of Acyclovir in Human Plasma Samples by HPLC Method with UV Detection: Application to Single-Dose Pharmacokinetic Study","volume":"3","author":"Zendelovska","year":"2015","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_12","first-page":"5","article-title":"LC-MS\/MS in the Clinical Laboratory\u2014Where to From Here?","volume":"32","author":"Grebe","year":"2011","journal-title":"Clin. Biochem. Rev."},{"key":"ref_13","unstructured":"(2023, January 01). ICH Q2(R2) Guideline on Validation of Analytical Procedures. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf."},{"key":"ref_14","first-page":"19","article-title":"Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry","volume":"30","author":"Pitt","year":"2009","journal-title":"Clin. Biochem. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pigliasco, F., Cafaro, A., Simeoli, R., Barco, S., Magnasco, A., Faraci, M., Tripodi, G., Goffredo, B.M., and Cangemi, G. (2021). A UHPLC-MS\/MS Method for Therapeutic Drug Monitoring of Aciclovir and Ganciclovir in Plasma and Dried Plasma Spots. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101379"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jchromb.2008.04.022","article-title":"Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection","volume":"867","author":"Dao","year":"2008","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.17145\/jab.18.020","article-title":"Determination of ganciclovir and acyclovir in human serum using liquid chromatography-tandem mass spectrometry","volume":"4","author":"Alffenaar","year":"2018","journal-title":"J. Appl. Bioanal."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"\u00c4rlemalm, A., Helld\u00e9n, A., Karlsson, L., and Carlsson, B.J.B.C. (2022). Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC\u2013MS\/MS. Biomed. Chromatogr., 36.","DOI":"10.1002\/bmc.5315"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/bmc.1192","article-title":"Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography","volume":"23","author":"Weller","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/bmc.258","article-title":"A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography","volume":"17","author":"Teshima","year":"2003","journal-title":"Biomed. Chromatogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1211\/146080800128735593","article-title":"Simultaneous determination of aciclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions","volume":"6","author":"Shibata","year":"2000","journal-title":"Pharm. Pharmacol. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"ref_23","unstructured":"(2023, January 01). ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1002\/cptx.92","article-title":"Analysis of Immunosuppressant Drugs in Whole Blood by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS\/MS)","volume":"84","author":"Pablo","year":"2020","journal-title":"Curr. Protoc. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1515\/CCLM.2008.243","article-title":"Measurement of mycophenolic acid in plasma or serum by a commercial enzyme inhibition technique in comparison with a high performance liquid chromatography method","volume":"46","author":"Bunch","year":"2008","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:54Z","timestamp":1760105094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052685"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052685","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}